Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease.
Mesalamine has been the first-line of therapy in patients with inflammatory bowel disease (IBD) since the 1960s. This article serves as a review of the different 5-aminosalicylic acid compounds, release formulations, use and dosing in the treatment of IBD, in particular ulcerative colitis.
Sonu
Irene
I
University of Pennsylvania School of Medicine, Suite 100, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104, USA.
Lin
Ming Valerie
MV
Blonski
Wojciech
W
Lichtenstein
Gary R
GR
D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D000636:Aminosalicylic Acids